Literature DB >> 11342981

Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.

H Iwase1, Y Ando, S Ichihara, S Toyoshima, T Nakamura , S Karamatsu, Y Ito, H Yamashita, T Toyama, Y Omoto, Y Fujii, S Mitsuyama, S Kobayashi.   

Abstract

BACKGROUND: The increasing use of mammographic screening has led to an increased detection of ductal carcinoma in situ (DCIS) of the breast. The detailed biological characteristics of DCIS and a new classification of DCIS based on these characteristics are needed.
METHODS: Immunohistochemical studies were performed to assess the expression of c-erbB-2 (ErbB-2), estrogen receptor (ER), p53 and proliferative activity (Ki-67) in 65 patients with pure DCIS and 60 with invasive ductal carcinoma (IDC). We classified pure DCIS tumors using three classifications, the architectural, Nottingham, and Van Nuys classifications.
RESULTS: ErbB-2, ER and p53 staining was positive in 34%, 66% and 21% of patients with DCIS, respectively, and 58%, 42% and 33% in patients with IDC, respectively. Ki-67 stained positively in 1.5% of patients with DCIS and 11.2% of patients with IDC. The comedo type showed a high rate of positive ErbB-2 and p53 staining. The cribriform and papillary types showed a high rate of positive ER staining. Under the Van Nuys classification, ErbB-2, p53 and Ki-67 expression were highest in the group with high nuclear grade and lowest in the group with non-high nuclear grade without necrosis.
CONCLUSION: Although the biological markers of IDC tended to suggest aggressive behavior more so than those of DCIS, these differences were based on the histological sub-type, comedo or non-comedo. The Van Nuys classification best defined the subgroups of DCIS with a distinct expression pattern of biological markers, and the best candidates for breast-conserving surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342981     DOI: 10.1007/BF02967487

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  9 in total

Review 1.  Early breast cancer.

Authors:  Tomoyoshi Suzuki; Masakazu Toi; Shigehira Saji; Kazumi Horiguchi; Tomoyuki Aruga; Eiji Suzuki; Shinichiro Horiguchi; Nobuaki Funata; Katsuyuki Karasawa; Noriko Kamata
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

2.  Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.

Authors:  Rui-Jue Wang; Lin-Jie Lu; Liang-Bin Jin; Hong-Yuan Li; Guo-Sheng Ren; Kai-Nan Wu; Sheng-Chun Liu; Ling-Quan Kong
Journal:  Med Oncol       Date:  2013-12-12       Impact factor: 3.064

3.  Correlation Between Contrast-enhanced Ultrasound Characteristics (Qualitative and Quantitative) and Pathological Prognostic Factors in Breast Cancer.

Authors:  Irene Vraka; Evangelia Panourgias; Emmanouil Sifakis; Andreas Koureas; Petros Galanis; Dionysios Dellaportas; Athanasios Gouliamos; Aristides Antoniou
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

4.  Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state.

Authors:  Eline Boghaert; Derek C Radisky; Celeste M Nelson
Journal:  PLoS Comput Biol       Date:  2014-12-04       Impact factor: 4.475

5.  Expressions of Topo IIα and Ki67 in breast cancer and its clinicopathologic features and prognosis.

Authors:  Guangyu Sun; Shuyan Wang; Ying Wang
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

6.  Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.

Authors:  Irina Mordukhovich; Pavel Rossner; Mary Beth Terry; Regina Santella; Yu-Jing Zhang; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Mia M Gaudet; Susan E Steck; Sharon K Sagiv; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Kathleen Conway-Dorsey; Marilie D Gammon
Journal:  Environ Health Perspect       Date:  2009-11-18       Impact factor: 9.031

7.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

8.  Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.

Authors:  Yasuhiro Okumura; Yutaka Yamamoto; Zhenhuan Zhang; Tatsuya Toyama; Teru Kawasoe; Mutsuko Ibusuki; Yumi Honda; Ken-ichi Iyama; Hiroko Yamashita; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-10-06       Impact factor: 4.430

9.  Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

Authors:  Hiroko Yamashita; Mariko Nishio; Tatsuya Toyama; Hiroshi Sugiura; Zhenhuan Zhang; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.